RxDoctor Payments Data

Elizabeth Harris, APRN

Psychiatric/Mental Health · Wooster, OHNPI 1366030850

Payments from drug & device makers

$3,170in general payments, 2019–2025

Across 182 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$646
  • Alkermes, Inc.$566
  • Neurocrine Biosciences, Inc.$351
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$287
  • Lundbeck LLC$282
  • Teva Pharmaceuticals USA, Inc.$274
  • plus $764 from 9 others

What the payments were for

  • Food & beverage$3,08797%
  • Education$843%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,170 in reported general payments places this provider in the 80th percentile of 1,808 psychiatric/mental health providers in Ohio.

See all psychiatric/mental health providers in Ohio

Medicare billing

Part B allowed, 2024
$13,497
Medicare patients
37
Services billed
123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate71$242,292
AristadaAripiprazole Lauroxil33$102,073
Abilify MaintenaAripiprazole21$51,766
LybalviOlanzapine/Samidorphan Malate26$46,510
VraylarCariprazine Hcl29$43,088
RexultiBrexpiprazole13$18,650
Risperdal ConstaRisperidone Microspheres31$17,202
Lurasidone Hcl72$14,653
TrintellixVortioxetine Hydrobromide18$11,858
Aripiprazole109$6,263
Chlorpromazine Hcl46$5,577
Clozapine43$2,767
Desvenlafaxine Succinate ErDesvenlafaxine Succinate37$2,616
Divalproex Sodium ErDivalproex Sodium59$2,496
Paliperidone ErPaliperidone26$2,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$101$259,494102 claims
Alkermes, Inc.Aristada, Lybalvi$566$148,58359 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$187$70,41634 claims
AbbVieVraylar$646$43,08829 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$17$11,85818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,808 psychiatric/mental health providers in Ohio.

Other psychiatric/mental health in Wooster

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →